Pulse nav.journalClub النقاشات النشطة الرائج استكشاف الأسئلة الباحثون

Download the App

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

© Synapse Social LLC, 2026

سياسة الخصوصية

الرئيسية استكشاف nav.journalClub الرائج

⌘+K

Multiple myeloma: 2022 update on diagnosis, risk stratification, and management | Synapse

May 13, 2022Open Access

Multiple myeloma: 2022 update on diagnosis, risk stratification, and management

Key Points

Key points are not available for this paper at this time.

Abstract

A triplet regimen is usually needed at relapse, with the choice of regimen varying with each successive relapse.

Read Full Paperexternally

Like

Bookmark

Share

View Full Paper

Like

Bookmark

Share

View Full Paper

Cite This Study

S. Vincent Rajkumar (Fri,) studied this question.

synapsesocial.com/papers/69d83663f4e559c61eae2e6b https://doi.org/https://doi.org/10.1002/ajh.26590

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.2019 · 27 citations
2Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial2020 · 124 citations
3Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome2018 · 35 citations
4Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial2016 · 191 citations
5Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial2009 · 371 citations